# Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

> **NCT02915302** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 1950 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluzone Quadrivalent vaccine, No Preservative
- **BIOLOGICAL:** Fluzone Quadrivalent vaccine, No Preservative

## Key facts

- **NCT ID:** NCT02915302
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-23
- **Primary completion:** 2017-03-06
- **Final completion:** 2017-03-06
- **Target enrollment:** 1950 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02915302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02915302, "Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02915302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*